Docket Room.
HB 616·TX·house

Relating to the addition of Benzimidazole-opioids to Penalty Group 1-B of the Texas Controlled Substances Act.

IntroducedFiled Nov 9, 2026
Sponsor: Brent Money (R)
Latest Action

Filed

Nov 9, 2026

Email me when HB 616 moves

Committee action, floor votes, amendments and hearings. Free, no card, no password.

Already have an account? Track HB 616. By continuing you agree to the Terms and Privacy Policy.

Legislative status

  1. Introduced
  2. In Committee
  3. Reported by Committee
  4. Floor Vote Scheduled
  5. Passed One Chamber
  6. Passed Both Chambers
  7. Sent to Executive
  8. Signed into Law

Summary

HB 616 would place benzimidazole‑opioid drugs into Penalty Group 1‑B under Texas law, treating them as high‑risk controlled substances. The change would affect manufacturers, distributors, prescribers and anyone possessing or using those drugs by subjecting them to the penalties that apply to Group 1‑B substances. The measure seeks to address concerns about the potential abuse of this emerging class of opioids.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Ask about HB 616

3 free questions a day, no account

Sponsors

  • Brent Money (R) · sponsor

Bill text

Read the official text ↗

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Share

Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.

Track this bill

Get an email when HB 616 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track HB 616 free

Or ask your AI assistant about HB 616 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice